Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Celiac disease and risk of myasthenia gravis - nationwide population-based study.

Thawani SP, Brannagan TH, Lebwohl B, Green PHR, Ludvigsson JF.

BMC Neurol. 2018 Mar 12;18(1):28. doi: 10.1186/s12883-018-1035-2.

2.

Type 1 Diabetes, Celiac Disease, and Neuropathy-A Nationwide Cohort Study.

Thawani S, Brannagan TH 3rd, Lebwohl B, Mollazadegan K, Green PHR, Ludvigsson JF.

J Clin Neuromuscul Dis. 2017 Sep;19(1):12-18. doi: 10.1097/CND.0000000000000174.

PMID:
28827484
3.

Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH 3rd, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceição I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ.

Muscle Nerve. 2017 Nov;56(5):901-911. doi: 10.1002/mus.25563. Epub 2017 Apr 7.

PMID:
28063170
4.

Reply.

Farhad K, Brannagan TH 3rd.

Muscle Nerve. 2017 Feb;55(2):291. doi: 10.1002/mus.25427. Epub 2016 Nov 4. No abstract available.

PMID:
27701749
5.

REPLY.

Farhad K, Brannagan TH 3rd.

Muscle Nerve. 2016 Nov;54(5):983-984. doi: 10.1002/mus.25237. Epub 2016 Jul 17. No abstract available.

PMID:
27389826
6.

Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.

Kaplan A, Brannagan TH 3rd.

Muscle Nerve. 2017 Apr;55(4):476-482. doi: 10.1002/mus.25271. Epub 2016 Dec 23.

PMID:
27463215
7.

Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.

Dixit N, Castano A, Farr MJ, Traub R, Lentzsch S, Brown RS Jr, Maurer MS, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2016 Mar;17(3):142-5. doi: 10.1097/CND.0000000000000110.

PMID:
26905915
8.

Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.

Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh PB, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group.

Muscle Nerve. 2016 May;53(5):717-25. doi: 10.1002/mus.25070. Epub 2016 Mar 3.

PMID:
26852139
9.

Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument.

Gwathmey KG, Conaway MR, Sadjadi R, Joshi A, Barnett C, Bril V, Ng E, David W, Gable K, Guptill JT, Hobson-Webb LD, Dineen J, Hehir M, Brannagan TH 3rd, Byun E, Adler M, Burns TM.

Muscle Nerve. 2016 Jun;54(1):9-17. doi: 10.1002/mus.24985. Epub 2015 Dec 29.

10.

Causes of neuropathy in patients referred as "idiopathic neuropathy".

Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd.

Muscle Nerve. 2016 Jun;53(6):856-61. doi: 10.1002/mus.24969. Epub 2015 Dec 29.

PMID:
26561790
11.

Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.

Leitch MM, Sherman WH, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2015 Sep;17(1):1-5. doi: 10.1097/CND.0000000000000083.

PMID:
26301372
12.

Neuromuscular complications of hematopoietic stem cell transplantation.

Ruzhansky KM, Brannagan TH 3rd.

Muscle Nerve. 2015 Oct;52(4):480-7. doi: 10.1002/mus.24724. Epub 2015 Aug 19. Review.

PMID:
26044357
13.

Treatment of chronic inflammatory demyelinating polyneuropathy.

Kleyman I, Brannagan TH 3rd.

Curr Neurol Neurosci Rep. 2015 Jul;15(7):47. doi: 10.1007/s11910-015-0563-z. Review.

PMID:
26008811
14.

Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.

Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2015 Jun;16(4):202-9. doi: 10.1097/CND.0000000000000077.

PMID:
25996966
15.

Risk of Neuropathy Among 28,232 Patients With Biopsy-Verified Celiac Disease.

Thawani SP, Brannagan TH 3rd, Lebwohl B, Green PH, Ludvigsson JF.

JAMA Neurol. 2015 Jul;72(7):806-11. doi: 10.1001/jamaneurol.2015.0475.

PMID:
25962148
16.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

17.

Discordant phenotype in monozygotic female twins with Lys35Thr TTR familial amyloidotic polyneuropathy.

Ruzhansky K, Scoon J, Weimer LH, Maurer MS, Berk JL, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2014 Sep;16(1):1-6. doi: 10.1097/CND.0000000000000040.

PMID:
25137508
18.

Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

Goldman JS, Quinzii C, Dunning-Broadbent J, Waters C, Mitsumoto H, Brannagan TH 3rd, Cosentino S, Huey ED, Nagy P, Kuo SH.

JAMA Neurol. 2014 Jun;71(6):771-4. doi: 10.1001/jamaneurol.2013.5762.

19.

Quality improvement in neurology: Distal symmetric polyneuropathy quality measures.

England JD, Franklin G, Gjorvad G, Swain-Eng R, Brannagan TH 3rd, David WS, Dubinsky RM, Smith BE.

Neurology. 2014 May 13;82(19):1745-8. doi: 10.1212/WNL.0000000000000397. Epub 2014 Apr 2.

20.

Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies.

Juranek JK, Kothary P, Mehra A, Hays A, Brannagan TH 3rd, Schmidt AM.

Brain Behav. 2013 Nov;3(6):701-9. doi: 10.1002/brb3.176. Epub 2013 Oct 8.

Supplemental Content

Loading ...
Support Center